PDS >> Efficacy Models >> Gastrointestinal

Gastrointestinal In vivo Models for Drug Discovery

 

Gastrointestinal (GI) disease is characterized by abnormalities in the gastrointestinal tract which includes the esophagus, liver, gallbladder, stomach, pancreas, intestines and colon. Inflammation in these areas can cause a variety of GI diseases or dysfunctions and can be difficult to diagnose. According to the CDC, in the United States alone, inflammatory bowel disease (Crohn's disease or ulcerative colitis) affects over 1 million people.

Pharmacology Discovery Services has conducted in vivo testing for both side-effect profiling and efficacy in GI disease for over 30 years.  Our models allow examination of GI motility and colonic function or you may test agents designed to prevent a variety of GI related diseases.  We also employ a broad range of outcome measures to assess GI safety and/or therapeutic efficacy of novel test articles.  All models are validated in a dose-dependent manner with approved benchmark positive controls to assure high-quality, reproducible data is provided to our clients.  To meet the needs of your specific gastrointestinal drug discovery project we also have the flexibility and expertise to develop custom in vivo models.


Speak with
an expert

Download our
model list

 

 


Validated Gastrointestinal In Vivo Models

In order to help you advance your drug candidate(s) we offer a number of relevant qualified models that include:

  • Gastric acid secretion and ulcers
  • Mucosal irritation
  • Gastrointestinal motility
  • Inflammatory bowel disease (IBD)
  • Irritable bowel syndrome (IBS)
  • Emesis, including 5-HT emetic models

In Vivo Pharmacology Expertise

Each of our Technical Directors specializes in selected therapeutic areas so they may provide expert scientific support to our clients.  This involves consulting with clients to identify an appropriate model to meet their scientific objectives, designing studies and writing the custom protocols and statements of work (SOWs) to meet quality assurance guidelines.  They also work closely with our Study Directors to assure that SOWs are clear and that all methods and timelines are feasible.  Our laboratory staff also averages 15 years of experience conducting in vivo pharmacology studies. 

Gastrointestinal In Vivo Models
Model Name Item Number Species Price/Animal ($USD)
Candida albicans azole resistant (R357), Systemic Infection Kidney CFU/g 609040 Mouse 260
Cholecystokinin, CCK1 (CCKA) Antagonism 517010 Mouse 190
Cholecystokinin, CCK2 (CCKB) Agonism/Antagonism 517510 Rat 220
Emesis, Suncus murinus 530820 Suncus 720
Eschericia coli (ATCC 700336), UTI Model, CFU 608380 Mouse 400
Gastric Acidity, Basal 533000 Rat 225
Gastric Acidity, Pentagastrin 534000 Rat 225
Gastric Acidity, Pylorus Ligation 534100 Rat 260
Gastric Emptying, Test Meal 534550 Rat 260
Gastric Irritation 535020 Rat 220
Gastric Ulcers, Aspirin 535900 Rat 220
Gastric Ulcers, Ethanol 536000 Rat 220
Gastrointestinal Motility 537920 Mouse 190
Gastrointestinal Motility 537940 Rat 260
Gastrointestinal Motility, Colonic Propulsion, Clonidine 538100 Mouse 220
Gastrointestinal Motility, Colonic Propulsion, Loperamide 538110 Mouse 220
Gastrointestinal Motility, Colonic Propulsion, Morphine 538120 Mouse 220
Gastrointestinal Motility, 5-HTP Induced Diarrhea 538200 Mouse 175
Gastrointestinal Motility Conditioned Fear Stress Induced Diarrhea  538300 Rat 360
Hyperuricemia, Potassium Oxonate Induced 546600 Rat 275
Inflammation, DSS-induced Colitis 553420 Mouse 350
Inflammation, Inflammatory Bowel Disease 553400 Rat 535
Inflammation, TNBS-induced Colitis 553405 Mouse 300
Inflammation, TNBS-induced Colitis 553410 Rat 535
Renal, Acute Renal Failure, Ischemia/Reperfusion 575000 Rat 770
Renal, Chronic Failure, Remnant Kidney 575500 Rat 900
Renal Function 576000 Rat 250